Cardiac Marker Testing Devices Market To Cross Towering Growth Line Up To 2026 | by Bio-Rad Laboratories, Inc., Siemens Medical Solutions USA, Inc., Randox Laboratories Ltd. Etc.

Cardiac markers are diagnostic tool, which are used for diagnosis and risk detection in patients suffering from chest pain, acute coronary syndrome (ACS), and acute myocardial infraction (MI). Cardiac marker test detects the endogenous substances, which are released during the blood circulation mainly when the heart is damaged or stressed, thereby, assessing risk and directing appropriate therapy that improves clinical outcome in high-risk patients. Cardiac markers have application in hospitals to either detect cardiac injury or to evaluate future risk of cardiovascular disease.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1039

Myoglobin, homocysteine, troponin T (cTnT), troponin I (cTnl), creatine kinase-MB (CK-MB), and C-reactive protein (CRP) are cardiac markers that are used for the assessment of acute myocardial infraction. However, CK-MB, cTnl, and cTnT are used for identifying and managing acute coronary syndrome in high-risk patients. Cardiac troponin I and T are most preferred and extensively used cardiac marker for myocardial injury, due to their higher sensitivity and specificity for diagnosis of myocardial infraction.

According to Journal of the American Medical Association (JAMA), in 2016, acute coronary syndrome is was the major cause of morbidity and mortality worldwide. It is also responsible for over 1 million hospital admissions in the U.S. annually.  Increasing incidence of myocardial infraction (MI) or heart attack, acute coronary syndrome, and consistent development in cardiac markers by existing market players are some of the factors that are expected to fuel growth of the cardiac marker testing devices market. Moreover, high blood pressure, high LDL cholesterol, smoking, unhealthy diet, diabetes, obesity, physical inactivity, and excessive alcohol consumption are some other factors which leads to coronary heart disease and associated disorders. This in turn, is expected to drive growth of the global cardiac marker testing devices market over the forecast period.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1039

According to a report by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), in 2016, around 47% of the geriatric population in the U.S. have at least one of three major risk factor of cardiovascular disease (CVD), which includes uncontrolled high blood pressure, uncontrolled high LDL cholesterol, and smoking. However, controlling these factors could reduce the risk of heart attack by 80%. BBI Solutions, a developer and manufacturer of raw material and finished test platforms for the in-vitro diagnostic tests, in 2017 launched myoglobin antibiotics as a cardiac marker. These cardiac marker were tested in ELISA assay before using it in commercial assay procedures and patient’s screening processes. The launch of new cardiac marker allows expansion of BBI solution’s antibodies portfolio in the global cardiac marker testing devices market.

Moreover, according to the American Heart Association (AHA), around 790,000 people in the U.S. encounter heart attack every year. Furthermore, annual incidence of heart attack in the U.S. are around 580,000 cases and 210,000 recurrent cases. According to AHA 2017 report, myocardial infraction diagnosis cost around US$ 11.5 billion and coronary heart disease cost around US$ 10.4 billion, were estimated as the most expensive hospital discharge diagnosis. The number of cardiovascular disease cases is expected to increase to 131.2 million by 2035, accounting to nearly 45% of the total U.S. population, with expected cost to reach US$ 1.1 trillion, which in turn, is expected to drive growth of the cardiac marker testing devices market over the forecast period.

Major acquisitions by key players are expected to drive growth of the cardiac marker testing devices market

In 2017, U.S. Federal Trade Commission (FTC) allowed US$ 5.3 billion of acquisition of Alere’s point-of-care cardiac marker testing business to Abbott Laboratories. The deal between Abbott Laboratories and Alere created the world’s largest point-of-care testing business, which significantly strengthened and grow Abbott’s diagnostic presence in cardiac marker testing devices market.

Moreover, in 2017, FTC approved the deal of Alere’s Triage B-type Naturietic Peptide (BNP) assay business and Triage MeterPro toxicology and cardiovascular business with Quidel Corporation. The acquisition of Alere’s point-of-care cardiac marker testing business is expected to improve Quidel’s portfolio of rapid diagnostic testing solutions.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/cardiac-marker-testing-devices-market-1039

Key Development in Cardiac Marker Testing Devices Market

• In September 2019, Sanskritech Smart Solutions Pvt Ltd launched a self-monitoring health diagnostic Point of Care Testing (POCT) system ‘Swayam AHM’. The device can perform 55 basic and advanced tests including cardiac marker, hormone marker, blood-borne disease and other POC tests.
• In September 2019, Hangzhou AllTest Biotech CO., LTD launched its Cardiac troponin T (cTnT) rapid test for the detection of the cardiac marker
• In May 2016, Royal Philips launched handheld blood test, the Minicare I-20 system, for rapid diagnosis of a heart attack at the point of care. The devices measures the level of cardiac troponin I (cTnI), a protein excreted by the heart muscle into the blood following a heart attack.
• In November 2016, Abbott received CE marking for i-STAT Alinity System, an innovative handheld blood testing platform. The device is designed to perform and analyze the blood tests on a single device, ranging from blood chemistries to cardiac markers.

Key players in the cardiac marker testing devices market

Some of the key players operating in the global cardiac marker testing devices market include Bio-Rad Laboratories, Inc., Siemens Medical Solutions USA, Inc., Randox Laboratories Ltd., Abbott Laboratories, Becton, Dickinson and Company, Helomics Corp., LSI Medience Corporation, F.Hoffmann-La Roche Ltd., Enzo Biochem Inc., Ortho Clinical Diagnostics,

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.